<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01377623</url>
  </required_header>
  <id_info>
    <org_study_id>10-02185</org_study_id>
    <nct_id>NCT01377623</nct_id>
  </id_info>
  <brief_title>Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion</brief_title>
  <official_title>Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the proposed study is to examine the effect of DEX on the inflammatory response in
      major surgery. More importantly, the investigators will correlate changes in the
      concentration of inflammatory mediators with meaningful clinical outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgical injury to tissue causes a variety of profound physiologic reactions which are
      essential for the restoration of an organisms' homeostasis. The inflammatory response
      involves a surge of stress hormones (i.e. ACTH, cortisol, catecholamines), activation of the
      complement system, migration of leukocytes to the site of injury, the release of cytokines
      (i.e. interleukins, tumor necrosis factor), as well as other cellular products (i.e.
      superoxide radicals, proteases, growth factors) (1-3). An appropriate inflammatory cascade is
      essential for tissue reconstitution and infection control. The associated impairment of
      multiple organ function is generally mild, because of the physiological reserve of the
      biological systems. However, a systemic inflammatory response may also lead to postoperative
      complications in the elderly, neonates, and patients with significant co-morbidity (4, 5).
      Indeed, mediators of inflammation may induce fatigue and prolong convalescence in healthy
      patients. On the other hand, dysregulation or suppression of the inflammatory process may
      lead to improper wound healing, infection and, as demonstrated recently, even an increase in
      cancer recurrence due to reduction in natural killer cell activity (6, 7).

      Anesthetic management may affect both immunostimulatory and immunosuppressive mechanisms
      either directly by modulating functions of immune cells or indirectly by attenuating the
      stress response. For example, inhalational anesthetics inhibit neutrophil function and
      depress lymphocyte proliferation while increasing pro-inflammatory cytokine levels (8, 9)).
      Propofol also inhibits neutrophil and monocyte function, and has strong anti-inflammatory and
      anti-oxidative effects (10). Opioids attenuate the direct cell immune response, but have only
      minimal effects on systemic inflammatory responses (11). It is expected that the choice of
      anesthetic technique may disturb the balance between pro- and anti-inflammatory responses
      thus affecting clinical outcomes. A most advantageous anesthetic choice would enhance or have
      a neutral effect on cellular immunity while minimizing contribution to the systemic
      inflammatory response.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Recovery Score (QoR-40)</measure>
    <time_frame>Post-operative Day 3</time_frame>
    <description>The QoR-40 is a 40 item questionnaire in which each question is answered with a score of 1-5. QoR-40 scores range from 40 (extremely poor quality of recovery) to 200 (excellent quality of recovery).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of TNF-alpha</measure>
    <time_frame>Post-operative Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of IL-1a</measure>
    <time_frame>Post-operative Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of IL-6</measure>
    <time_frame>Post-operative Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of IL-8</measure>
    <time_frame>Post-operative Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Spinal Stenosis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine group</intervention_name>
    <description>Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).</description>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo group</intervention_name>
    <description>Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult (&gt; 18) male or female who will undergo surgery for spinal fusion with general
             anesthesia.

          2. If female, subject is non-lactating and is either:

               -  Not of childbearing potential

               -  Of childbearing potential but is not pregnant at time of baseline as determined
                  by pre-surgical pregnancy testing.

          3. Subject is ASA physical status 1, 2, or 3.

        Exclusion Criteria:

          1. Cognitively impaired (by history)

          2. Subject requires chronic antipsychotic history

          3. Subject is anticipated to require an additional surgery within 90 days after the
             intended spinal fusion

          4. Subject known to be in liver failure

          5. Subject has received treatment with alpha-2-agonist or antagonist within 2 weeks of
             study entry

          6. Subject for whom opiates, benzodiazepines, DEX are contraindicated

          7. Chronic use of steroids/NSAIDs

          8. Patients with serious bradycardia related arrhythmias, i.e. 2nd degree block.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Bekker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Urban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Langone Medical Center, Department of Anesthesiology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bekker A, Haile M, Kline R, Didehvar S, Babu R, Martiniuk F, Urban M. The effect of intraoperative infusion of dexmedetomidine on the quality of recovery after major spinal surgery. J Neurosurg Anesthesiol. 2013 Jan;25(1):16-24. doi: 10.1097/ANA.0b013e31826318af.</citation>
    <PMID>22824921</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2011</study_first_submitted>
  <study_first_submitted_qc>June 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2011</study_first_posted>
  <results_first_submitted>March 14, 2016</results_first_submitted>
  <results_first_submitted_qc>October 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 14, 2016</results_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal fusion</keyword>
  <keyword>Inflammatory response</keyword>
  <keyword>Inflammatory markers</keyword>
  <keyword>Dexmedetomidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Spinal Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine Group (PFD)</title>
          <description>Anesthesia maintained with propofol/fentanyl/dexmedetomidine</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group (PFS)</title>
          <description>Anesthesia maintained with propofol/fentanyl/saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline data is only available for those participants who completed the study</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Group</title>
          <description>Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).</description>
        </group>
        <group group_id="B2">
          <title>Dexmedetomidine Group</title>
          <description>Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="11.1"/>
                    <measurement group_id="B2" value="55.3" spread="12.3"/>
                    <measurement group_id="B3" value="56.18" spread="11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quality of Recovery Score (QoR-40)</title>
        <description>The QoR-40 is a 40 item questionnaire in which each question is answered with a score of 1-5. QoR-40 scores range from 40 (extremely poor quality of recovery) to 200 (excellent quality of recovery).</description>
        <time_frame>Post-operative Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine Group (PFD)</title>
            <description>Anesthesia maintained with propofol/fentanyl/dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group (PFS)</title>
            <description>Anesthesia maintained with propofol/fentanyl/saline</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Recovery Score (QoR-40)</title>
          <description>The QoR-40 is a 40 item questionnaire in which each question is answered with a score of 1-5. QoR-40 scores range from 40 (extremely poor quality of recovery) to 200 (excellent quality of recovery).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.04" spread="2.76"/>
                    <measurement group_id="O2" value="169.3" spread="3.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of TNF-alpha</title>
        <time_frame>Post-operative Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine Group (PFD)</title>
            <description>Anesthesia maintained with propofol/fentanyl/dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group (PFS)</title>
            <description>Anesthesia maintained with propofol/fentanyl/saline</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of TNF-alpha</title>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="3.8" upper_limit="12.7"/>
                    <measurement group_id="O2" value="7.9" lower_limit="2.1" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of IL-1a</title>
        <time_frame>Post-operative Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine Group (PFD)</title>
            <description>Anesthesia maintained with propofol/fentanyl/dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group (PFS)</title>
            <description>Anesthesia maintained with propofol/fentanyl/saline</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of IL-1a</title>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" lower_limit="1.4" upper_limit="3.6"/>
                    <measurement group_id="O2" value="2.58" lower_limit="1.4" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of IL-6</title>
        <time_frame>Post-operative Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine Group (PFD)</title>
            <description>Anesthesia maintained with propofol/fentanyl/dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group (PFS)</title>
            <description>Anesthesia maintained with propofol/fentanyl/saline</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of IL-6</title>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" lower_limit="27.3" upper_limit="122.8"/>
                    <measurement group_id="O2" value="50.0" lower_limit="11.2" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of IL-8</title>
        <time_frame>Post-operative Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine Group (PFD)</title>
            <description>Anesthesia maintained with propofol/fentanyl/dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group (PFS)</title>
            <description>Anesthesia maintained with propofol/fentanyl/saline</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of IL-8</title>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" lower_limit="12.6" upper_limit="31.2"/>
                    <measurement group_id="O2" value="16.4" lower_limit="6.2" upper_limit="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine Group (PFD)</title>
          <description>Anesthesia maintained with propofol/fentanyl/dexmedetomidine</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group (PFS)</title>
          <description>Anesthesia maintained with propofol/fentanyl/saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alex Bekker</name_or_title>
      <organization>UMDNJ-New Jersey Medical School</organization>
      <phone>973-972-5007</phone>
      <email>alex.bekker@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

